Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.39 |
| ▸ | TET3 | O43151 | 2/20 | 0.39 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8416906 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2SLC22A6GABRR1LMNATDP1 | |
| SCHEMBL8417005 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2SLC22A6GABRR1LMNATDP1 | |
| Malic Acid SCHEMBL6863763 | 0.77 | SMN1; SMN2 (0.88) | SMN1; SMN2SLC22A6GABRR1LMNATDP1 | |
| SCHEMBL19912995 | 0.76 | OR51E2 (0.36) | SMN1; SMN2SLC22A6GABRR1LMNATET2 | |
| Malic Acid SCHEMBL856 | 0.75 | — | — | |
| Malic Acid SCHEMBL14125844 | 0.75 | SMN1; SMN2 (1.00) | SMN1; SMN2SLC22A6GABRR1LMNATDP1 | |
| Malic Acid SCHEMBL98496 | 0.75 | — | — | |
| Malic Acid SCHEMBL256122 | 0.75 | — | — | |
| Malic Acid SCHEMBL89131 | 0.75 | SMN1; SMN2 (1.00) | SMN1; SMN2SLC22A6GABRR1LMNATDP1 | |
| Malic Acid SCHEMBL31673489 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231527-A1 | SYNTHESIS OF ORGANIC ACIDS FROM ALPHA-KETO ACIDS | FURMAN UNIVERSITY | 2020-07-23 | — | — | US | claimed |
| EP-0884390-B1 | Method for producing an optically active compound | KYOWA HAKKO KOGYO KK (JP) | 2006-05-10 | — | — | EP | claimed |
| CN-119330823-A | Long carbon chain hydroxyl-containing branched dicarboxylic acid, and preparation method and application thereof | 华中师范大学 | 2025-01-21 | — | — | CN | disclosed |
| US-20230190910-A1 | SCAFFOLDED HIV-1 VACCINE IMMUNOGENS | SCRIPPS RESEARCH INST (US) | 2023-06-22 | — | — | US | disclosed |
| US-11505519-B2 | Synthesis of organic acids from α-keto acids | FURMAN UNIVERSITY (US) | 2022-11-22 | — | — | US | disclosed |
| US-11452771-B2 | Scaffolded HIV-1 Env GP140 trimer immunogen | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-09-27 | — | — | US | disclosed |
| EP-3911624-A1 | SYNTHESIS OF ORGANIC ACIDS FROM ALPHA-KETO ACIDS | Furman University (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20200231527-A1 | SYNTHESIS OF ORGANIC ACIDS FROM ALPHA-KETO ACIDS | FURMAN UNIVERSITY | 2020-07-23 | — | — | US | disclosed |
| WO-2020150568-A1 | SYNTHESIS OF ORGANIC ACIDS FROM ALPHA-KETO ACIDS | FURMAN UNIVERSITY (US) | 2020-07-23 | — | — | WO | disclosed |
| US-10711043-B2 | Compositions and vaccines comprising vesicles and methods of using the same | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190016761-A1 | Compositions and Vaccines Comprising Vesicles and Methods of Using the Same | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2019-01-17 | — | — | US | disclosed |
| EP-1877567-A2 | POLYPEPTIDES AND BIOSYNTHETIC PATHWAYS FOR THE PRODUCTION OF MONATIN AND ITS PRECURSORS | CARGILL, INCORPORATED (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007103989-A9 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORP (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007103389-A9 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | CARGILL INC (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007103389-A2 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | CARGILL, INCORPORATED (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103989-A2 | ALDOLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2006116487-A2 | POLYPEPTIDES AND BIOSYNTHETIC PATHWAYS FOR THE PRODUCTION OF MONATIN AND ITS PRECURSORS | CARGILL, INCORPORATED (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-0692539-B1 | Process for producing an optically active gamma-hydroxy-L-glutamic acid | KYOWA HAKKO KOGYO KK (JP) | 1999-09-22 | — | — | EP | disclosed |
| US-5643769-A | Process for producing an optically active γ-hydroxy-L-glutamic acid | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0692539-A2 | Process for producing an optically active gamma-hydroxy-L-glutamic acid | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231527-A1 | SYNTHESIS OF ORGANIC ACIDS FROM ALPHA-KETO ACIDS | HOGA1, BCKDK, PCCA | SMN1; SMN2 4397/4885SLC22A6 1831/4885GABRR1 1215/4885 |
| US-11505519-B2 | Synthesis of organic acids from α-keto acids | HOGA1, BCKDK, KHK | SMN1; SMN2 4489/4885SLC22A6 1680/4885GABRR1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.